212 related articles for article (PubMed ID: 8574158)
1. The role of alpha-interferon in essential thrombocythaemia, polycythaemia vera and myelofibrosis with myeloid metaplasia (MMM): a concise update.
Sacchi S
Leuk Lymphoma; 1995 Sep; 19(1-2):13-20. PubMed ID: 8574158
[TBL] [Abstract][Full Text] [Related]
2. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
3. Cytogenetic conversion in a case of polycythaemia vera treated with interferon-alpha.
Messora C; Bensi L; Vecchi A; Longo R; Giacobbi F; Temperani P; Bevini M; Emilia G; Sacchi S
Br J Haematol; 1994 Feb; 86(2):402-4. PubMed ID: 8199036
[TBL] [Abstract][Full Text] [Related]
4. Treatment of polycythaemia vera and essential thrombocythaemia.
Tefferi A; Silverstein MN
Baillieres Clin Haematol; 1998 Dec; 11(4):769-85. PubMed ID: 10640216
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG.
Michiels JJ; Barbui T; Finazzi G; Fuchtman SM; Kutti J; Rain JD; Silver RT; Tefferi A; Thiele J
Leuk Lymphoma; 2000 Jan; 36(3-4):239-53. PubMed ID: 10674896
[TBL] [Abstract][Full Text] [Related]
6. Interferon-alpha therapy in polycythemia vera and essential thrombocythemia.
Elliott MA; Tefferi A
Semin Thromb Hemost; 1997; 23(5):463-72. PubMed ID: 9387205
[TBL] [Abstract][Full Text] [Related]
7. [Interferon-alpha in the treatment of myeloproliferative syndromes].
Ballarino P; Castello G; Lerza R
Recenti Prog Med; 1994 Nov; 85(11):546-50. PubMed ID: 7855389
[TBL] [Abstract][Full Text] [Related]
8. Expertise-based management in essential thrombocythemia and polycythemia vera.
Finazzi G; Barbui T
Cancer J; 2007; 13(6):372-6. PubMed ID: 18032974
[TBL] [Abstract][Full Text] [Related]
9. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Jun; 88(6):507-16. PubMed ID: 23695894
[TBL] [Abstract][Full Text] [Related]
10. Polycythaemia vera and essential thrombocythaemia: current treatment strategies.
Penninga EI; Bjerrum OW
Drugs; 2006; 66(17):2173-87. PubMed ID: 17137402
[TBL] [Abstract][Full Text] [Related]
11. Cytoreductive effect of recombinant alpha interferon in patients with myelofibrosis with myeloid metaplasia.
Barosi G; Liberato LN; Costa A; Ascari E
Blut; 1989 Jun; 58(6):271-4. PubMed ID: 2736307
[TBL] [Abstract][Full Text] [Related]
12. Morphometric study of the bone marrow in polycythemia vera following interferon-alpha therapy.
Franco V; Florena AM; Aragona F; Campesi G
Pathol Res Pract; 1993 Feb; 189(1):52-7. PubMed ID: 8516217
[TBL] [Abstract][Full Text] [Related]
13. Interferon alpha-2b as treatment for Philadelphia-negative chronic myeloproliferative disorders with excessive thrombocytosis.
Lazzarino M; Vitale A; Morra E; Gagliardi A; Bernasconi P; Torromeo C; Inverardi D; Burgio V; Castello A; Bernasconi C
Br J Haematol; 1989 Jun; 72(2):173-7. PubMed ID: 2757963
[TBL] [Abstract][Full Text] [Related]
14. alpha Interferon treatment of essential thrombocythaemia and other myeloproliferative disorders with excessive thrombocytosis.
Yataganas X; Meletis J; Plata E; Viniou N; Deligiannis F; Tsekoura C; Voscaridou E; Boussiotis V; Rombos J; Vayopoulos G
Eur J Cancer; 1991; 27 Suppl 4():S69-71. PubMed ID: 1799484
[TBL] [Abstract][Full Text] [Related]
15. Interferon treatment in polycythaemia vera.
Reilly JT; Vellenga E; De Wolff JT
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():143-8. PubMed ID: 8951785
[TBL] [Abstract][Full Text] [Related]
16. Clinico-Pathological Profile And Outcomes Of Patients With Polycythaemia Vera, Essential Thrombocythaemia And Idiopathic Myelofibrosis: A Tertiary Care Center Experience From Southern Pakistan.
Shaikh MS; Shaikh MU; Adil SN; Khurshid M; Ahmed ZA
J Ayub Med Coll Abbottabad; 2016; 28(2):293-297. PubMed ID: 28718562
[TBL] [Abstract][Full Text] [Related]
17. The optimal management of polycythaemia vera.
Spivak JL
Br J Haematol; 2002 Feb; 116(2):243-54. PubMed ID: 11841424
[No Abstract] [Full Text] [Related]
18. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
19. Pegylated interferon for the treatment of early myelofibrosis: correlation of serial laboratory studies with response to therapy.
O'Neill C; Siddiqi I; Brynes RK; Vergara-Lluri M; Moschiano E; O'Connell C
Ann Hematol; 2016 Apr; 95(5):733-8. PubMed ID: 26961933
[TBL] [Abstract][Full Text] [Related]
20. [Use of interferon in the treatment of chronic myeloproliferative disorders].
Robak T
Acta Haematol Pol; 1992; 23(2 Suppl 1):30-7. PubMed ID: 1488870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
